Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of MigraineGlobeNewsWire • 02/20/20
Axsome Therapeutics (AXSM) Gains But Lags Market: What You Should KnowZacks Investment Research • 01/28/20
Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant DepressionGlobeNewsWire • 01/22/20
Axsome Therapeutics: A Company With Booming Catalysts And A Remarkable Innovation In Treating DepressionSeeking Alpha • 12/24/19
Axsome Therapeutics Announces Closing of $200 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 12/23/19